Skip to main content

Chronic Inflammatory Demyelinating Polyneuropathy

Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
NCT01184846 | PHASE 3 | INTERVENTIONAL

The objective of this study is to demonstrate the efficacy and safety of Privigen in subjects with CIDP.

Trial Information
22 Sites
31 Participants
Recruiting
18 Years to 65 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Study Site
Bruxelles,Belgium
Study Site
Edegem,Belgium
Study Site
Gent,Belgium
Study Site
Leuven,Belgium
Study Site
Helsinki,Finland
Study Site
Turku,Finland
Study Site
Vaasa,Finland
Study Site
Limoges,France
Study Site
Lyon,France
Study Site
Marseille,France
Study Site
Montpellier,France
Study Site
Paris,France
Study Site
Berlin,Germany
Study Site
Feldberger Seenlandschaft,Germany
Study Site
Göttingen,Germany
Study Site
Itzehoe,Germany
Study Site
Prien,Germany
Study Site
Schwedt,Germany
Study Site
Würzburg,Germany
Study Site
Krakow,Poland
Study Site
Lublin,Poland
Study Site
Wroclaw,Poland

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov